EPS for Sucampo Pharmaceuticals, Inc. (SCMP) Expected At $0.34

February 15, 2018 - By Marie Mckinney

 EPS for Sucampo Pharmaceuticals, Inc. (SCMP) Expected At $0.34
Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.32, from 1.33 in 2017Q2. It improved, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 31 funds opened positions while 58 raised stakes. 29.83 million shares or 20.72% more from 24.71 million shares in 2017Q2 were reported.
Arizona State Retirement has 13,000 shares for 0% of their portfolio. Pnc Fincl Services Inc stated it has 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Ameriprise Fincl Inc stated it has 213,246 shares. Morgan Stanley accumulated 0% or 157,332 shares. Parkside State Bank reported 37 shares. Trexquant Inv Lp has invested 0.03% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Federated Invsts Pa has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Bowling Portfolio Mngmt reported 0.21% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Mason Street Advsrs Llc stated it has 6,367 shares. Stevens Capital Mngmt Limited Partnership reported 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). 195 were reported by Advisory Services Net Limited Co. Nuveen Asset Mngmt Ltd Company stated it has 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Invesco stated it has 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). 26,331 are owned by Comerica Bank. Lsv Asset, a Illinois-based fund reported 2.47 million shares.

Since September 11, 2017, it had 0 insider purchases, and 3 insider sales for $24.83 million activity. Kuno Sachiko sold $12.00M worth of stock or 1.00M shares. On Thursday, December 7 the insider Kiener Peter A sold $825,000.

Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $0.34 EPS on March, 14.They anticipate $0.34 EPS change or 50.00 % from last quarter’s $0.68 EPS. SCMP’s profit would be $16.01M giving it 13.24 P/E if the $0.34 EPS is correct. After having $0.27 EPS previously, Sucampo Pharmaceuticals, Inc.’s analysts see 25.93 % EPS growth. It closed at $18 lastly. It is down 5.30% since February 15, 2017 and is downtrending. It has underperformed by 22.00% the S&P500.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Sucampo Pharma had 46 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was upgraded by Mizuho on Wednesday, April 20 to “Buy”. Mizuho maintained the stock with “Neutral” rating in Friday, November 13 report. UBS downgraded it to “Hold” rating and $18.0 target in Friday, January 5 report. The rating was maintained by Jefferies with “Hold” on Wednesday, March 9. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) earned “Buy” rating by Maxim Group on Wednesday, August 26. The rating was initiated by H.C. Wainwright on Monday, August 24 with “Buy”. As per Friday, January 15, the company rating was maintained by Mizuho. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Neutral” rating given on Friday, October 9 by Mizuho. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Friday, December 8 by Mizuho. Mizuho maintained it with “Hold” rating and $18.0 target in Wednesday, January 3 report.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The company's marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

More important recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Bizjournals.com which released: “Sucampo Pharmaceuticals closes on its $1.2B sale to a UK company” on February 13, 2018, also Prnewswire.com published article titled: “Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of …”, Prnewswire.com published: “Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.” on February 13, 2018. More interesting news about Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was released by: Bizjournals.com and their article: “Shareholders sue Sucampo, claim proposed sale undervalues the company” with publication date: February 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.